usp107 Antibody

What is USP107 and what is its functional significance in Schizosaccharomyces pombe?

USP107 (Uniprot Q8WZK0) is a protein found in Schizosaccharomyces pombe (fission yeast), also known as strain 972 / ATCC 24843. While complete functional characterization is still developing, USP107 likely belongs to the ubiquitin-specific protease family, which is involved in deubiquitination processes. These enzymes typically cleave ubiquitin from substrate proteins, thereby regulating protein stability, localization, and function. In S. pombe, such proteins may play critical roles in cell cycle regulation, DNA damage response, and stress adaptation mechanisms. The study of USP107 can provide insights into conserved ubiquitin-dependent regulatory pathways across eukaryotes, making antibodies against this protein valuable research tools .

How should USP107 antibody be stored to maintain optimal activity?

Proper storage of USP107 antibody is crucial for maintaining its functionality and specificity. Upon receipt, USP107 antibody should be stored at either -20°C or -80°C, with the latter being preferred for long-term storage. Repeated freeze-thaw cycles can significantly degrade antibody quality and should be strictly avoided. For optimal preservation, researchers should consider aliquoting the antibody into single-use volumes immediately upon receipt. When handling the antibody during experiments, it should be kept on ice and returned to appropriate storage conditions promptly after use. Documentation of freeze-thaw cycles and storage conditions in laboratory notebooks is strongly recommended for troubleshooting unexpected experimental outcomes .

What applications are suitable for USP107 antibody in S. pombe research?

While specific application validation data for the USP107 antibody is limited in the available sources, antibodies against ubiquitin-specific proteases are typically employed in several common research techniques. These likely include Western blotting for protein expression analysis, immunoprecipitation for protein-protein interaction studies, immunocytochemistry or immunofluorescence for subcellular localization, and chromatin immunoprecipitation for DNA-protein interaction analyses. The polyclonal nature of many such antibodies (as suggested by the product code format) makes them potentially versatile across multiple applications, though each application would require specific optimization. Researchers should design pilot experiments with appropriate controls to validate the antibody for their specific application before proceeding with full-scale experiments .

What experimental validation methods are recommended to confirm USP107 antibody specificity?

Confirming antibody specificity is critical for meaningful research outcomes. For USP107 antibody, researchers should implement a multi-faceted validation approach. First, negative controls using samples where USP107 is knocked out or significantly downregulated should be employed. In S. pombe, this can be achieved through gene deletion strains or RNA interference techniques. Second, overexpression systems can serve as positive controls, ideally using tagged versions of USP107 that can be detected with independent antibodies. Third, pre-absorption tests, where the antibody is pre-incubated with purified recombinant USP107 protein before application to samples, can confirm binding specificity. The appearance of a single band of appropriate molecular weight (~128 kDa, by analogy with USP7) in Western blot analysis would further support specificity. For immunofluorescence applications, co-localization studies with orthogonal markers of the expected subcellular compartment provide additional validation .

How do experimental conditions affect USP107 antibody performance in Western blotting?

The performance of USP107 antibody in Western blotting is likely affected by multiple experimental variables that require optimization. Based on protocols for similar antibodies, researchers should consider: (1) Sample preparation methods—denaturation conditions (temperature, buffer composition) significantly impact epitope accessibility; (2) Blocking conditions—5% non-fat milk may be suitable for reducing non-specific binding, but BSA might be preferable depending on the specific antibody properties; (3) Antibody concentration—titration experiments starting at 2 μg/mL and testing serial dilutions can identify optimal signal-to-noise ratios; (4) Incubation conditions—both temperature (4°C vs. room temperature) and duration (1 hour vs. overnight) should be systematically tested; (5) Washing stringency—buffer composition (TBST vs. PBST) and wash duration affect background signal; (6) Detection system—chemiluminescence vs. fluorescence-based systems offer different sensitivity profiles. Additionally, sample denaturing conditions may need modification if USP107 forms complexes with other proteins that affect epitope accessibility .

What considerations are important when designing immunoprecipitation experiments with USP107 antibody?

Immunoprecipitation (IP) experiments with USP107 antibody require careful experimental design. Researchers should consider: (1) Lysis conditions—gentle non-ionic detergents (e.g., 0.5% NP-40) are generally preferable, but stronger conditions may be necessary if USP107 forms tight complexes; (2) Pre-clearing—incubating lysates with protein G beads prior to antibody addition reduces non-specific binding; (3) Antibody immobilization—direct coupling to beads using crosslinkers like dimethyl pimelimidate can prevent co-elution of antibody heavy chains that may interfere with detection; (4) Controls—parallel IPs with non-specific IgG from the same species as the USP107 antibody are essential; (5) Washing stringency—balance between removing non-specific interactions while preserving specific ones must be empirically determined; (6) Elution methods—different approaches (pH, ionic strength, denaturing conditions) may yield different results depending on binding affinity. For studying ubiquitinated proteins or deubiquitination activity, including N-ethylmaleimide in lysis buffers is crucial to inhibit deubiquitinases that might alter the ubiquitination status during sample processing .

How can researchers investigate USP107's potential role in ubiquitin pathways in S. pombe?

Investigation of USP107's role in ubiquitin pathways requires an integrated experimental approach. First, researchers should establish whether USP107 possesses deubiquitinase activity through in vitro deubiquitination assays using purified recombinant USP107 and ubiquitin chains of different linkage types (K48, K63, etc.). Second, substrate identification can be approached through proteomics analysis of proteins that accumulate in ubiquitinated form when USP107 is deleted or inhibited. Third, genetic interaction screens with known ubiquitin pathway components can reveal functional relationships. Fourth, analysis of ubiquitin chain dynamics in response to cellular stresses (UV, oxidative stress, heat shock) in wild-type versus USP107-deficient cells can provide insights into pathway-specific roles. By analogy with other ubiquitin-specific proteases like USP7, which regulates the tumor suppressor p53 through deubiquitination, researchers should investigate whether USP107 plays roles in stress response, cell cycle regulation, or DNA damage repair in S. pombe .

What protocol modifications are recommended when using USP107 antibody for immunofluorescence studies?

For successful immunofluorescence studies with USP107 antibody in S. pombe, several protocol modifications should be considered: (1) Fixation method—paraformaldehyde (3-4%) is generally suitable, but methanol fixation may better preserve certain epitopes; (2) Permeabilization—Triton X-100 (0.1-0.5%) is commonly used, but the concentration and duration should be optimized as excessive permeabilization may disrupt nuclear architecture where many ubiquitin-specific proteases localize; (3) Blocking—5% normal serum from the secondary antibody's host species reduces background; (4) Antibody concentration—start with 2 μg/mL based on similar antibodies and adjust through titration experiments; (5) Incubation time—overnight incubation at 4°C often yields better results than shorter incubations; (6) Detection system—signal amplification methods may be necessary if endogenous expression is low. Additionally, counterstaining with DAPI and markers for specific subcellular compartments allows precise localization assessment. For quantitative analyses, standardized image acquisition parameters and analysis protocols should be established .

How should researchers troubleshoot weak or non-specific signals when using USP107 antibody?

When encountering weak or non-specific signals with USP107 antibody, systematic troubleshooting should follow these steps: (1) For weak signals—increase antibody concentration incrementally, extend incubation time, reduce washing stringency, use more sensitive detection systems, or employ signal amplification methods; (2) For non-specific signals—increase blocking agent concentration (5-10%), extend blocking time, increase wash duration and number, reduce antibody concentration, pre-absorb antibody with unrelated proteins, or use alternative blocking agents; (3) For high background—ensure complete removal of SDS from samples, increase washing stringency, check for secondary antibody cross-reactivity, or optimize the detection system's exposure time. Critical controls include: processing samples without primary antibody, using non-specific IgG as primary antibody, and including positive and negative biological controls. If problems persist, alternative antibody lots or clones should be tested. Detailed documentation of all optimization steps helps establish robust protocols for reproducible results .

What quantification methods are appropriate for analyzing USP107 expression or activity data?

Quantitative analysis of USP107 expression or activity requires appropriate methods depending on the experimental technique. For Western blot analysis, densitometry using software like ImageJ with normalization to loading controls (β-actin, α-tubulin) is standard practice. For more precise quantification, researchers should consider: (1) Working within the linear dynamic range of detection; (2) Including calibration curves with recombinant standards; (3) Using technical replicates to assess measurement variability. For immunofluorescence, mean fluorescence intensity measurements with background subtraction and appropriate statistical analysis across multiple cells and fields should be performed. For functional studies of deubiquitinating activity, enzyme kinetics approaches measuring substrate processing rates can be employed. In all cases, statistical analysis should account for biological variability, with data presented as mean ± standard deviation or standard error from at least three independent biological replicates. This approach ensures robust quantification that can detect biologically meaningful changes in USP107 expression or activity .

How should researchers interpret conflicting results between different assays involving USP107 antibody?

When facing conflicting results between different assays using USP107 antibody, researchers should implement a systematic reconciliation approach: (1) Consider epitope accessibility differences between techniques—Western blotting detects denatured epitopes while immunofluorescence relies on native conformations; (2) Evaluate method-specific limitations—each technique has different sensitivity thresholds and dynamic ranges; (3) Assess potential interference from protein modifications or interaction partners across methods; (4) Examine the timing of observations—protein levels and localization can change rapidly in response to cell cycle progression or stress; (5) Validate with orthogonal methods—complement antibody-based detection with mRNA analysis, tagged protein variants, or mass spectrometry. When reporting such conflicts in publications, researchers should transparently discuss all results with potential explanations for discrepancies rather than selectively reporting consistent findings. This comprehensive approach strengthens data interpretation and may reveal novel biological insights about USP107 regulation .

What experimental design best addresses the potential cross-reactivity between USP107 and other USP family members?

Addressing potential cross-reactivity between USP107 and other USP family members requires a multi-faceted approach: (1) Computational analysis—sequence alignment of the immunogen region across all USP family members in S. pombe to identify potential cross-reactive proteins; (2) Knockout validation—testing the antibody in strains where USP107 and closely related USPs are individually deleted; (3) Overexpression systems—expressing tagged versions of different USP family members and testing for antibody reactivity; (4) Competitive binding assays—pre-incubating the antibody with recombinant proteins of related USPs before application to samples; (5) Mass spectrometry validation—identifying all proteins immunoprecipitated by the antibody. The experimental design should include both positive controls (samples with confirmed USP107 expression) and negative controls (samples lacking USP107 but containing other USP family members). This comprehensive approach ensures confident attribution of experimental observations specifically to USP107 rather than to cross-reactive family members .

How can researchers leverage USP107 antibody for studying evolutionary conservation of ubiquitin pathways?

Studying evolutionary conservation of ubiquitin pathways using USP107 antibody requires a comparative approach across species. Researchers should: (1) Test cross-reactivity of the S. pombe USP107 antibody with homologous proteins in related species through Western blotting; (2) For species where cross-reactivity is confirmed, perform comparative analyses of expression patterns, subcellular localization, and stress responses; (3) For species lacking cross-reactivity, identify homologs through bioinformatics and generate specific antibodies for comparison; (4) Design complementation experiments where homologs from different species are expressed in USP107-deficient S. pombe to assess functional conservation; (5) Compare substrate specificity across species using immunoprecipitation followed by mass spectrometry; (6) Analyze conservation of post-translational modifications and regulatory mechanisms through phospho-specific antibodies and kinase inhibitors. This evolutionary perspective can reveal core conserved functions versus species-specific adaptations in ubiquitin regulatory pathways, potentially identifying fundamental mechanisms preserved throughout eukaryotic evolution .

What considerations are important when designing experiments to study USP107's potential role in stress response pathways?

Designing experiments to investigate USP107's role in stress response requires careful consideration of multiple factors: (1) Stress selection—test multiple stressors (oxidative, heat shock, DNA damage, nutrient deprivation) as DUBs often show stress-specific functions; (2) Temporal dynamics—analyze both acute (minutes to hours) and adaptive (hours to days) responses through time-course experiments; (3) Concentration gradients—use multiple intensities of each stressor to identify threshold-dependent effects; (4) Subcellular redistribution—monitor USP107 localization changes during stress using fractionation and immunofluorescence; (5) Proteasome inhibition—determine whether USP107's role is proteasome-dependent by using inhibitors like MG132; (6) Substrate identification—perform immunoprecipitation under stress conditions followed by mass spectrometry to identify stress-specific interactors; (7) Genetic interaction studies—create double mutants with known stress response genes to identify pathway relationships. Controls should include wild-type cells under identical conditions and cells with mutations in other USP family members to distinguish USP107-specific functions from general DUB functions .

What integrated approaches combining antibody-based detection with genetic techniques are most informative for USP107 research?

The most informative research on USP107 integrates antibody-based detection with complementary genetic approaches. This integrated strategy should include: (1) Correlation of protein levels (antibody detection) with mRNA expression (RT-qPCR) to identify post-transcriptional regulatory mechanisms; (2) CRISPR-based tagging of endogenous USP107 with fluorescent proteins or epitope tags for live-cell imaging and validation of antibody specificity; (3) Creation of conditional expression systems (e.g., thiamine-repressible promoters in S. pombe) to study dose-dependent phenotypes while monitoring protein levels with the antibody; (4) Systematic mutation of key domains (catalytic, substrate-binding, regulatory) with antibody-based detection of resulting protein stability and localization; (5) Synthetic genetic array analysis to identify genetic interactions, coupled with antibody-based detection of protein level changes in double mutants. This multi-dimensional approach yields mechanistic insights impossible to obtain through either antibody-based or genetic techniques alone, providing a comprehensive understanding of USP107 function in cellular contexts .

How can researchers effectively combine USP107 antibody-based experiments with ubiquitination site mapping techniques?

Effective integration of USP107 antibody-based experiments with ubiquitination site mapping requires a coordinated research strategy. Researchers should: (1) Use USP107 antibody for immunoprecipitation of the enzyme, followed by mass spectrometry to identify associated substrates; (2) Perform parallel experiments with catalytically inactive USP107 mutants to trap substrate interactions; (3) Employ denaturing conditions (1% SDS with heating at 95°C for 10 minutes) when isolating ubiquitinated proteins to disrupt non-covalent interactions; (4) Implement diGly remnant antibody-based enrichment of ubiquitinated peptides from cells with wild-type versus USP107-deficient backgrounds; (5) Validate identified substrates through targeted approaches using USP107 antibody to monitor changes in substrate ubiquitination states; (6) Perform in vitro deubiquitination assays with recombinant USP107 and synthetic ubiquitinated peptides corresponding to putative substrate sites. For all experiments, appropriate controls include non-specific IgG for immunoprecipitation and parallel analysis of samples treated with deubiquitinase inhibitors like N-ethylmaleimide. This integrated approach allows precise mapping of USP107's substrate specificity at the level of individual ubiquitination sites .